Investment Thesis
ExaGen demonstrates revenue growth of 19.7% and healthy 59% gross margins, but faces critical operational sustainability issues. Operating losses of -$3.4M and negative operating cash flow of -$10.4M indicate the business cannot fund itself, while 1.58x debt/equity leverage and negative interest coverage of -6.2x create solvency risk. With -$10.6M annual free cash flow, the company has approximately 2 years of cash runway at current burn rates before facing dilutive capital requirements.
Strengths
- Revenue growth of 19.7% YoY demonstrates market traction in medical diagnostics sector
- Gross margin of 59% reflects strong underlying unit economics and pricing power
- Current ratio of 3.47x provides adequate short-term liquidity buffer
Risks
- Operating losses of -$3.4M despite revenue growth indicate inability to achieve cost structure efficiency
- Negative operating cash flow of -$10.4M and free cash flow of -$10.6M demonstrate unsustainable burn rate
- High leverage (1.58x debt/equity) with negative interest coverage (-6.2x) creates imminent solvency risk and dilution probability
Key Metrics to Watch
- Quarterly progress toward operating profitability and positive operating cash flow
- Cash burn rate and remaining runway before forced capital raise
- Gross margin sustainability as company scales and debt service pressure increases
Financial Metrics
Revenue
17.3M
Net Income
-4.0M
EPS (Diluted)
$-0.17
Free Cash Flow
-10.6M
Total Assets
52.0M
Cash
21.5M
Profitability Ratios
Gross Margin
59.0%
Operating Margin
-19.7%
Net Margin
-22.9%
ROE
-27.5%
ROA
-7.6%
FCF Margin
-61.5%
Balance Sheet & Liquidity
Current Ratio
3.47x
Quick Ratio
3.47x
Debt/Equity
1.58x
Debt/Assets
72.2%
Interest Coverage
-6.22x
Long-term Debt
22.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T06:58:42.721394 |
Data as of: 2026-03-31 |
Powered by Claude AI